Skip to main content

Agilent Supports UC Dublin Fellowship

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies is funding a fellowship at University College Dublin's Conway Institute of Biomolecular and Biomedical Research, the company said today.

The company's grant will fund the appointment of Ben Collins as the Agilent Technologies Newman Fellow in Quantitative Proteomics. Collins' research will focus on development and application of advanced liquid chromatography/mass spectrometry methodologies for a range of projects.

Agilent has an existing collaboration with the Proteome Research Center at the Conway Institute that focuses on development and application of advanced workflows for analysis of protein content in biosamples.

"As a leading technology partner to academia, the funding of the Newman Fellowship reflects our core belief that investing in the next generation of thought leaders is a crucial part of moving sciences forward," Agilent Ireland's Country General Manager Padraig McDonnell said in a statement.

UCD Director of Trust and Foundations Jessica Kavanagh said that the Newman Fellowship provides "opportunities at postdoctoral level for high-caliber national and international researchers, generously funded by philanthropy, business, and industry … Working alongside their academic mentors, the Fellows contribute greatly to the academic research agenda of their particular discipline and to university life in general."

The Newman Fellows are funded for a two-year period to conduct a major research project that will lead to publication, and the fellowships are aimed at building on the complementary strengths and needs of the university and the corporate sector.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.